您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > Encequidar(HM-30181 HM-30181A)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Encequidar(HM-30181 HM-30181A)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Encequidar(HM-30181 HM-30181A)图片
CAS NO:849675-66-7
规格:≥98%
包装与价格:
包装价格(元)
5mg电议
10mg电议
25mg电议
50mg电议
100mg电议
250mg电议

产品介绍

Encequidar (formerly HM-30181; HM30181; HM30181A) is a novel, potent, selective, and orally bioavailable inhibitor of the adenosine triphosphate (ATP)-binding cassette (ABC) transporter P-gp (P-glycoprotein). It was designed to improve the oral bioavailability of drugs that are P-gp substrates which may otherwise be pumped out of cells by P-gp, leading to drug resistance. Encequidar was supported by FDA in March 2021 for the new drug application for combination with oral paclitaxel in the treatment of patients with metastatic breast cancer. Oral paclitaxel and encequidar is the first world taxane to demonstrate superiority in radiologically confirmed tumor response rate, with reduced neuropathy and alopecia compared to IV paclitaxel in women with metastatic breast cancer. Encequidar showed the highest potency (IC(50)=0.63nM) among several MDR1 inhibitors, including cycloporin A, XR9576, and GF120918, and effectively blocked transepithelial transport of paclitaxel in MDCK monolayers (IC(50)=35.4nM). Encequidar is currently under clinical trials.

纯度:≥98%

CAS:849675-66-7